DK1551952T3 - Udvælgelse og anvendelse af mælkesyrebakterier til formindskelse af betændelse forårsaget af helicobacter - Google Patents

Udvælgelse og anvendelse af mælkesyrebakterier til formindskelse af betændelse forårsaget af helicobacter Download PDF

Info

Publication number
DK1551952T3
DK1551952T3 DK03751682.0T DK03751682T DK1551952T3 DK 1551952 T3 DK1551952 T3 DK 1551952T3 DK 03751682 T DK03751682 T DK 03751682T DK 1551952 T3 DK1551952 T3 DK 1551952T3
Authority
DK
Denmark
Prior art keywords
lactobacillus
strain
cell
cells
atcc pta
Prior art date
Application number
DK03751682.0T
Other languages
English (en)
Inventor
Bo Möllstam
Eamonn Connolly
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Application granted granted Critical
Publication of DK1551952T3 publication Critical patent/DK1551952T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (9)

1. Biologisk ren kultur af Lactobacillus coryniformis-stamme MM7, ATCC PTA-4660.
2. Biologisk ren kultur af Lactobacillus reuteri-stamme MM2-3, ATCC PTA-4659.
3. Cellefri supernatant kulturvæske isoleret fra en biologisk ren kultur af Lactobacillus reuteri-stamme MM2-3, ATCC PTA-4659.
4. Cellefri supernatant kulturvæske isoleret fra en biologisk ren kultur af Lactobacillus coryniformis-stamme MM7, ATCC PTA-4660.
5. Lactobacillus-stamme ifølge krav 1 eller krav 2 eller den cellefri supernatante kulturvæske ifølge krav 3 eller krav 4, til anvendelse ved nedsættelse af mave- og tarmkanalbetændelse forbundet med Helicobacter pylorl· infektion i mave-tarmkanalen hos pattedyr.
6. Produkt indeholdende celler af Lactobacillus-stammen ifølge krav 1 eller krav 2 eller den cellefri supernatante væske ifølge krav 3 eller krav 4.
7. Næringsmiddelsammensætning indeholdende et nedsvælgeligt bærestof og en H. Pylorl·forbundet betændelsesnedsættende bestanddel afledt fra en stamme af Lactobacillus valgt fra gruppen bestående af Lactobacillus coryniformis-stamme MM7, ATCC PTA-4660 og Lactobacillus reuteri-stamme MM2-3, ATCC PTA-4659, hvor bestanddelen indeholder celler af en biologisk ren kultur af stammen af Lactobacillus ifølge krav 1 eller krav 2, eller hvor bestanddelen indeholder den cellefri supernatante kulturvæske ifølge krav 3 eller krav 4.
8. Farmaceutisk sammensætning indeholdende et farmaceutisk bærestof og en H. Pylorl·forbundet betændelsesnedsættende bestanddel afledt fra en stamme af Lactobacillus valgt fra gruppen bestående af Lactobacillus coryniformis-stamme MM7, ATCC PTA-4660 og Lactobacillus reuteri-stamme MM2-3, ATCC PTA-4659, hvor bestanddelen indeholder celler af en biologisk ren kultur af stammen af Lactobacillus ifølge krav 1 eller krav 2, eller hvor bestanddelen indeholder den cellefri supernatante kulturvæske ifølge krav 3 eller krav 4.
9. Ernæringstilskud indeholdende et nedsvælgeligt bærestof og en H. Pylorl· forbundet betændelsesnedsættende bestanddel afledt fra en stamme af Lactobacillus valgt fra gruppen bestående af Lactobacillus coryniformis-stamme MM7, ATCC PTA-4660 og Lactobacillus reuteri-stamme MM2-3, ATCC PTA-4659, hvor bestanddelen indeholder celler af en biologisk ren kultur af stammen af Lactobacillus ifølge krav 1 eller krav 2, eller hvor bestanddelen indeholder den cellefri supernatante kulturvæske ifølge krav 3 eller krav 4.
DK03751682.0T 2002-10-07 2003-10-06 Udvælgelse og anvendelse af mælkesyrebakterier til formindskelse af betændelse forårsaget af helicobacter DK1551952T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/265,859 US7105336B2 (en) 2002-10-07 2002-10-07 Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
PCT/SE2003/001552 WO2004031368A1 (en) 2002-10-07 2003-10-06 Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Publications (1)

Publication Number Publication Date
DK1551952T3 true DK1551952T3 (da) 2016-12-12

Family

ID=32042542

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03751682.0T DK1551952T3 (da) 2002-10-07 2003-10-06 Udvælgelse og anvendelse af mælkesyrebakterier til formindskelse af betændelse forårsaget af helicobacter

Country Status (14)

Country Link
US (4) US7105336B2 (da)
EP (1) EP1551952B1 (da)
JP (2) JP4804755B2 (da)
KR (2) KR101064058B1 (da)
CN (1) CN1694954B (da)
AU (1) AU2003269756B2 (da)
BR (1) BR0314511A (da)
DK (1) DK1551952T3 (da)
ES (1) ES2602679T3 (da)
HU (1) HUE031627T2 (da)
MX (1) MXPA05003731A (da)
PT (1) PT1551952T (da)
WO (1) WO2004031368A1 (da)
ZA (1) ZA200502602B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
DE60232827D1 (de) * 2002-10-18 2009-08-13 Biogaia Ab Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
US20050281756A1 (en) 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
EP1706126A4 (en) * 2003-12-04 2009-07-01 Biofilms Strategies Inc METHOD AND COMPOSITIONS FOR PREVENTING THE PREPARATION OF BIOFILMS, REDUCING EXISTING BIOFILMS, AND REDUCING EXISTING BIOFILMS AND REDUCING BACTERIA POPULATIONS
CA2557834C (en) * 2004-03-04 2012-05-22 E-L Management Corporation Skin treatment method with lactobacillus extract
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
EP1703281A1 (fr) * 2005-03-16 2006-09-20 Compagnie Gervais Danone Souches bactériennes induisant une diminution de l'expression de Rbx1
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
DE102005062731A1 (de) 2005-12-22 2007-06-28 Organobalance Gmbh Neue Lactobacillus Stämme und deren Verwendung
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
CN101678052A (zh) * 2007-02-22 2010-03-24 于尔根·施赖岑米尔 用于在人中预防、抑制或消除变态反应的益生性革兰氏阳性细菌
CN101273738B (zh) * 2007-03-28 2011-06-01 哈尔滨正方科技有限公司 在常温下保持高活菌数的调配型酸性乳饮料的制备方法
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100886793B1 (ko) * 2007-06-26 2009-03-04 한경대학교 산학협력단 항균과 생균 활성을 가지는 신규한락토바실러스　코르니포미스 ｈｄ-０２ 균주 및 이의 용도
CN102115721B (zh) * 2008-05-08 2012-09-26 景岳生物科技股份有限公司 具有抗炎活性的乳杆菌分离株及其用途
JP5860396B2 (ja) * 2009-05-11 2016-02-16 ネステク ソシエテ アノニム ラクトバチルス・ジョンソニーＬａ１ＮＣＣ５３３（ＣＮＣＭＩ−１２２５）及び免疫障害
US20110293710A1 (en) 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
WO2013027087A1 (en) 2011-08-23 2013-02-28 Compagnie Gervais Danone A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection
RU2577994C1 (ru) * 2011-11-30 2016-03-20 Компани Жервэ Данон Реутерин-вырабатывающие lactobacillus brevis
CN104684565A (zh) * 2012-05-29 2015-06-03 达努塔·克鲁谢夫斯卡 在人类和兽医的预防和医疗中有用的、包含罗伊氏乳杆菌dan080的纳米产品及其医疗用途
MX2015005165A (es) 2012-10-25 2015-10-29 Gervais Danone Sa Cepas de streptococcus thermophilus para tratar infeccion por helicobacter pylori.
EP3040412A4 (en) * 2013-08-23 2017-04-05 Consejo Superior De Investigaciones Científicas (CSIC) Probiotic strain of lactobacillus reuteri exhibiting anti-helicobacter activity, a probiotic or biotherapeutic product comprising said strain, and the use thereof
BR112016031000B1 (pt) 2014-07-01 2022-01-25 Probi USA, Inc. Forma de dosagem em camadas e método para fazer a mesma
CN116396884A (zh) 2022-08-15 2023-07-07 江苏华熙益能生物科技有限公司 鼠李糖乳杆菌和一种抑制幽门螺杆菌的组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
DK0577903T3 (da) 1992-07-06 1998-04-06 Nestle Sa Antigastritisk middel
ATE474597T1 (de) * 1993-05-17 2010-08-15 Cytokine Pharmasciences Inc Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US5534253A (en) 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
AU756301B2 (en) * 1997-08-20 2003-01-09 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
GB9719238D0 (en) * 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
MXPA00007815A (es) * 1998-02-11 2002-04-24 Neurochem Inc Metodo para modular la activacion de macrofagos.
AU4438399A (en) * 1998-06-11 1999-12-30 University Of Medicine And Dentistry Of New Jersey Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
JP3046303B1 (ja) * 1999-06-24 2000-05-29 明治乳業株式会社 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性飲食品
JP4509250B2 (ja) * 1999-06-24 2010-07-21 明治乳業株式会社 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
KR100357668B1 (ko) 2000-02-19 2002-10-18 주식회사 한국야쿠르트 헬리코박터 필로리에 대해 항균활성을 갖는 락토바실러스애시도필러스 에이치 와이 2177, 락토바실러스 카제이에이치 와이2743 및 그를 이용한 유산균 제제, 발효유
WO2001062207A2 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
EP1296693A4 (en) * 2000-06-19 2005-05-25 Mucoprotec Pty Ltd IMMUNOTHERAPY AND PROBIOTIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL OR VIRAL INFECTIONS ON MUCOSAL SURFACES
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
MXPA04001999A (es) * 2001-09-05 2004-07-16 Vsl Pharmaceuticals Inc Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof

Also Published As

Publication number Publication date
PT1551952T (pt) 2016-11-23
EP1551952B1 (en) 2016-08-17
US7678553B2 (en) 2010-03-16
US7105336B2 (en) 2006-09-12
AU2003269756B2 (en) 2007-08-09
AU2003269756A1 (en) 2004-04-23
HK1079811A1 (zh) 2006-04-13
JP4804755B2 (ja) 2011-11-02
KR20110033943A (ko) 2011-04-01
KR101064058B1 (ko) 2011-09-08
US20090110670A1 (en) 2009-04-30
CN1694954A (zh) 2005-11-09
US20060251636A1 (en) 2006-11-09
JP2006501823A (ja) 2006-01-19
WO2004031368A1 (en) 2004-04-15
KR20050047107A (ko) 2005-05-19
CN1694954B (zh) 2010-05-12
BR0314511A (pt) 2005-08-09
ES2602679T3 (es) 2017-02-22
EP1551952A1 (en) 2005-07-13
KR101107453B1 (ko) 2012-01-19
MXPA05003731A (es) 2005-06-17
ZA200502602B (en) 2006-06-28
US20040067573A1 (en) 2004-04-08
JP5439315B2 (ja) 2014-03-12
HUE031627T2 (en) 2017-09-28
US20100129337A1 (en) 2010-05-27
US7960137B2 (en) 2011-06-14
JP2011021015A (ja) 2011-02-03

Similar Documents

Publication Publication Date Title
US7960137B2 (en) Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
KR102365414B1 (ko) 락토바실러스 파라카제이 균주 및 그 용도
DK2494031T3 (da) Hidtil ukendt lactobacillus plantarum og sammensætning omfattende denne
JP4415164B2 (ja) プロバイオティック・ラクトバチラス・サリバリウス株
RU2466185C2 (ru) ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum
JP2005508150A (ja) プロバイオティックラクトバチラスカゼイ株類
JP2005508617A (ja) プロバイオティックビフィドバクテリウム株類
CN1525863A (zh) 来自乳酸菌的脂磷壁酸及其调节革兰氏阴性菌、可能致病的革兰氏阳性菌介导的免疫应答的用途
Kim et al. Induction of cytokines and nitric oxide in murine macrophages stimulated with enzymatically digested lactobacillus strains
HK1079811B (en) Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter
RU2790297C9 (ru) Штамм lactobacillus paracasei и его применение
RU2790297C2 (ru) Штамм lactobacillus paracasei и его применение
KR20250019220A (ko) 장누수증후군 개선, 치료, 또는 예방용 유산균 및 이의 용도
Guerra A review on some chemical engineering and microbiological aspects considered in the production of highly concentrated probiotic cultures and bacteriocins by lactococci and lactobacilli
Varzakas et al. 12 Functional Dairy Foods and Flora Modulation
HK40040941A (en) Lactobacillus paracasei strain and use thereof
HK1056315A1 (en) Use of bifidobacteria in manufacture of medicaments for preventing diarrhea